Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer & Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STEAP2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STEAP2 Recombinant Protein (HEK293 Expressed, Endotoxin Controlled) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View STEAP2 Products |
| Gene Delivery | STEAP2 Lentivirus Premade Particles Full-length ORF for stable cell lines. Preserves native membrane conformation. |
View STEAP2 Products |
| Benchmark Ab | Anti-STEAP2 Recombinant Antibody (Benchmark Clone) Recombinant positive control for binding and imaging assays. |
View STEAP2 Products |
| Validator | STEAP2 siRNA Set For knockdown and specificity verification. |
View STEAP2 Products |
| Related Target A | STEAP1 High-sequence-homology family member; critical for selectivity counter-screening. |
View STEAP1 Products |
| Related Target B | STEAP4 Metalloreductase paralog; inclusion in off-target liability panels. |
View STEAP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation preservation (6-TM loops) | Lentivirus-based stable HEK293 cell lines expressing full-length STEAP2; maintains native glycosylation and loop architecture for antibody binding. |
| STEAP subfamily selectivity (STEAP1/3/4) | Sequence-verified Human STEAP1, STEAP2, and STEAP4 recombinant proteins (>95% purity) for strict cross-reactivity panels. |
| Cross-species toxicology bridging (Cyno/Mouse) | Cynomolgus and Mouse STEAP2 ortholog proteins available; sequence-verified for PK/PD and safety study translation. |
| Assay specificity controls | Validated STEAP2 siRNA and benchmark antibody included to confirm target-specific readouts. |
Live STEAP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STEAP2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADC and cell-therapy modalities. STEAP2 has emerged as a critical target for metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC), driven by its tumor-restricted expression and rapid internalization kinetics. As first-generation STEAP2-targeted programs advance through preclinical validation, the next wave of R&D is targeting combination strategies with androgen receptor (AR) pathway inhibitors and next-generation linker-payload optimization. Developers are actively seeking highly specific extracellular loop binders capable of rapid internalization without cross-reacting with hematologically vital targets like STEAP3.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Astellas, CDRI, Emerging Biotechs | Solid Tumors (mCRPC), Breast Cancer | Internalization Assay (Need stable full-length STEAP2 cell lines via lentivirus) |
| Bispecific / mAb | Amgen, Academic consortia | mCRPC, Refractory Solid Tumors | T-cell Activation Assay (Need Cyno cross-reactive proteins for toxicology) |
| CAR-T | Gene therapy innovators, Academic Institutions | Metastatic Solid Tumors (Prostate) | Cell-surface Density & Epitope Mapping (Need lentivirus transduction for flow cytometry) |
| Radioligand | Emerging Biotechs | mCRPC | Binding Affinity (Need STEAP2-specific epitope mapping domains) |
Key Mutations & Functional Domains
STEAP2 (UniProt Q8NFT2) contains a Ferric oxidoreductase domain, critical for its metalloreductase activity. Key mutations include dbSNP:rs194520, dbSNP:rs17863046, and dbSNP:rs13228098, which may influence protein function or disease association. These variants are important for designing selective therapeutics and understanding patient stratification.
Molecular Differentiation & Assay Strategy
For best-in-class STEAP2 drug development, the following differentiation needs and assay strategies are critical:
- Internalization Efficiency: Use pH-sensitive dye uptake assays with lentivirus-transduced stable cell lines to quantify internalization rate constants.
- Subfamily Selectivity: Employ STEAP1/2/4 homolog panels for cross-reactivity screening via SPR or Octet, requiring >100-fold selectivity over STEAP1.
- Cross-species Epitope Conservation: Utilize Human/Cyno/Mouse STEAP2 ortholog proteins for epitope mapping to ensure translational relevance.
- High-concentration Stability: Test antibody self-interaction and viscosity using STEAP2 ECD-Fc protein in crowding agents.
Related Target Recommendations
- STEAP1: Co-expressed in prostate cancer; essential for cross-reactivity screening and bispecific antibody development.
- STEAP4: Involved in metabolic pathways; inclusion in off-target panels to avoid systemic toxicity.
- PSMA (FOLH1): Gold standard prostate cancer marker; ideal for synergistic bispecific or combination therapy models.